NCT05844761Active, not recruiting
Real-time Motion Management During Prostate and Lung Radiotherapy
Source: ClinicalTrials.gov · Last updated 28 Jul 2026
Brief summary (registry, in English)
The goal of this interventional non-inferiority trial is to assess the accuracy of different real-time motion management radiotherapy techniques. The main question the study aims to answer are: * What are the target margins for radiotherapy with motion management that are not inferior to target margin without motion management * What are the dosimetric and geometrical accuracy to patient for the motion management techniques. Participants will answer QoL questionary, and the accuracy of treatment will be assessed from treatment data.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 132 (estimated)
- First submitted
- 11 Apr 2023
- Start date
- 1 May 2023
- Primary completion date
- Jun 2027
- Lead sponsor
- Region Skane
- Diseases
- Prostate cancer, Lung cancer
- NCT number
- NCT05844761
What you commit to
- Study type: Interventional
- Planned participants: 132
- From 1 May 2023 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with artificial Hip(s), lumbar spinal surgical rods or other large metallic pelvic implants
- Previous treatment with radiotherapy for lung cancer or lung metastasis
Other illness
- For prostate cancer patients:
- Unfeasible to track fiducials with kv imaging/existing online imaging systems
- For lung cancer patients:
Other
- Patient must have three gold fiducial markers inserted in the prostate
- Patients with overlapping implanted gold fiducials in X-ray imaging
- Idiopathic lung fibrosis
Who the study is looking for
- For prostate cancer patients:
- Patients histologically proven prostate adenocarcinoma
- Prostate specific antigen (PSA) obtained within three months prior to enrollment
- Localised prostate cancer at any stage eligible for radiotherapy: i.e. any T- or Gleason stage, but no pelvic lymph nodes can be included within the target to be treated
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Ability to understand and the willingness to sign a written informed consent document.
- Hypofractionated radiation therapy (HYPO) fractionated patients with a prescribed dose of 42.7Gy in 7 fractions.
- MRIOnly workflow meaning synthetic generated CT based on Magnetic resonance imaging (MRI)
- Patients over 40 years old
- For lung cancer patients:
- Lung cancer or localised metastatic disease from other cancer diagnoses, accepted for stereotactic radiotherapy to 45Gy in 3 fractions
- Lesion distinguishable on Computer Tomography and where the majority of adjacent tissue is the lung.
- Ability to understand and the willingness to sign a written informed consent document.
- Is able to perform treatment simulation
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Skåne University Hospital Coordinator of this site? Confirm its status | Lund | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.